Monday 29 May, 2023 01:58 AM
Site map | Locate Us | Login
   GMR Airports net loss widens to Rs 637 cr in Q4 FY23    Chambal Fertilisers Q4 PAT drops 61% YoY to Rs 94 cr    Karnataka Bank Q4 PAT soars 171% to Rs 354 cr    City Union Bank Q4 PAT rises 4% YoY to Rs 218 cr    Indigo Paints Q4 PAT climbs 41% YoY to Rs 49 cr    BHEL PAT slides 33% YoY to Rs 611 cr in Q4 FY23    BEML Q4 PAT rises 18% YoY to Rs 158 cr    ONGC reports net loss of Rs 248 cr in Q4 FY23    Sun Pharma gains on reporting turnaround Q4 performance    Manali Petrochemical tumbles after poor Q4 results    Grasim Inds skid after Q4 PAT declines 4% YoY to Rs 1,369 cr    M&M Q4 PAT rises 22% YoY to Rs 1,549 cr; board OKs dividend of Rs 16.25/share    eClerx Services gains after Q4 PAT jumps 12% YoY to Rs 132 cr    Page Industries Ltd leads losers in 'A' group    Ashapura Minechem Ltd leads losers in 'B' group 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Lupin gets USFDA nod for schizophrenia drug
21-Mar-23   15:36 Hrs IST

The approved ANDA is generic equivalent to Rexulti tablets of Otsuka Pharmaceutical Company. The drug is used to treat certain mental/mood disorders such as schizophrenia, depression. This product will be manufactured at company's Pithampur facility in India.

Brexpiprazole tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of $1,575 million in the U.S. (IQVIA MAT December 2022).

Meanwhile, the company announced that its alliance partner, Caplin Steriles received final approval from the USFDA to market Rocuronium Bromide Injection and Thiamine Hydrochloride Injection USP.

Mumbai-based Lupin is a transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The company reported 71.9% drop in net profit to Rs 153.5 crore despite of 3.8% rise in net sales to Rs to Rs 4,244.6 crore in Q3 FY23 over Q3 FY22.

The scrip rose 0.26% to Rs 647.90 on the BSE.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 26444954
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd